SRR934789
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 128.77792378449408
- age_years
- 30
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.535
- TGF_BETA_SIGNALING+0.480
- MITOTIC_SPINDLE+0.479
- G2M_CHECKPOINT+0.415
- MYC_TARGETS_V1+0.343
- UV_RESPONSE_DN+0.341
- WNT_BETA_CATENIN_SIGNALING+0.327
- HEDGEHOG_SIGNALING+0.274
- E2F_TARGETS+0.264
- ANDROGEN_RESPONSE+0.263
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.372
- KRAS_SIGNALING_DN-0.351
- COAGULATION-0.316
- SPERMATOGENESIS-0.292
- MYOGENESIS-0.266
- OXIDATIVE_PHOSPHORYLATION-0.222
- XENOBIOTIC_METABOLISM-0.198
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.188
- ANGIOGENESIS-0.184
- ALLOGRAFT_REJECTION-0.143
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9198B2FA-637D-44B2-B6E8-24B5681737AA | — | — | 0.907 |
| 2 | SRR934799 | — | — | 0.902 |
| 3 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.901 |
| 4 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.890 |
| 5 | SRR934758 | — | — | 0.886 |
| 6 | E55DA565-D03C-46BF-A498-0677AFA19D74 | — | — | 0.877 |
| 7 | SRR934805 | — | — | 0.876 |
| 8 | SRR934838 | — | — | 0.875 |
| 9 | SRR934870 | — | — | 0.871 |
| 10 | EFEDAFE3-FF81-47ED-97F6-1193EA375D77 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.535 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.480 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.479 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.415 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.343 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.341 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.327 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.274 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.264 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.263 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.258 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.257 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.233 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.108 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.104 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.095 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.088 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.085 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.077 | Idelalisib | — uncovered |